Business Context and Reporting Period
This Form 8-K filing by Altimmune, Inc. (Delaware) was submitted on May 8, 2018, reporting a corporate governance event. The company is headquartered in Gaithersburg, Maryland.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity data. The only financial disclosure relates to executive compensation for the newly appointed Acting Chief Financial Officer.
Material Changes
- Departure: Elizabeth Czerepak resigned as Chief Financial Officer and Executive Vice President of Corporate Development on May 8, 2018, to pursue other opportunities.
- Appointment: Will Brown, 36, was appointed as Acting Chief Financial Officer and Principal Accounting Officer effective May 8, 2018.
- Compensation: Mr. Brown will receive $27,000 per month in cash compensation plus a $1,000 monthly expense stipend.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Management commentary is limited to the announcement of the leadership transition and the commencement of a search for a permanent replacement for the CFO role.
Investor Verification Checklist
- Confirm the timeline for the permanent CFO search and the expected duration of Mr. Brown's acting role.
- Review Mr. Brown's prior consulting engagements to assess potential conflicts of interest.
- Monitor subsequent filings for the appointment of a permanent CFO and any changes to the company's financial reporting processes.